ReviewNPJ schizophrenia2021
Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development.
Review in NPJ schizophrenia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serotonin type 3 receptor (5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Pooled it
- Treatment effect modifiers of virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: an exploratory moderator analysis of clinical and demographic characteristics in the FaceYourFears trial.Psychological medicine · 2026Trial
- Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour.Nature communications · 2025Trial
- Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia.Schizophrenia bulletin · 2022Trial
- Expression and experience domains of negative symptoms in relation to social functioning in patients with schizophrenia: Results from a commonality analysis.Schizophrenia research. Cognition · 2026Article
- Arousal shapes motivation: an integrative framework for understanding motivational deficits.Translational psychiatry · 2026Review
- Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational Study.JMIR research protocols · 2026Observational
- Disrupted neural response timing and duration during hand movement preparation in schizophrenia spectrum disorder: An fMRI study.Scientific reports · 2026Article
- Associations between negative symptoms and resting-state functional connectivity within social brain networks among individuals with early psychosis.Schizophrenia (Heidelberg, Germany) · 2026Article
- Keep your participants close, but your informants closer? The added value of high and low contact informants to supplement self-report for the cognitive impairment of schizophrenia.Schizophrenia research. Cognition · 2026Article
- Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.Neuroscience applied · 2026Review
- Preliminary Findings From an Augmented Reality (AR) App Delivering Recovery-Oriented Cognitive Therapy for Negative Symptoms in Schizophrenia.Early intervention in psychiatry · 2026Article
- Impaired effort allocation in schizophrenia.Schizophrenia research. Cognition · 2025Article
- Relationship between cognitive reserve (education), social cognition and negative symptoms.Schizophrenia research. Cognition · 2025Article
- Spontaneous head movements during virtual clinical interviews help predict 12-months clinical outcomes in youth at clinical high risk for psychosis.Schizophrenia (Heidelberg, Germany) · 2025Article
- Robust missing data reconstruction in schizophrenia using tracking-removed autoencoder with fuzzy confidence integration.Scientific reports · 2025Article
- Blunted Ventral Striatal Reactivity to Social Reward Is Associated with More Severe Motivation and Pleasure Deficits in Psychosis.Schizophrenia bulletin · 2025Article
- Acute and Long-Term Consequences of Neonatal NMDA Blockade in the Cx3cr1 Knock-Out Mouse.Inflammation · 2025Article
- Comparative Effectiveness of Cognitive Behavioral Therapies in Schizophrenia and Schizoaffective Disorder: A Systematic Review and Meta-Regression Analysis.Journal of clinical medicine · 2025Review
- Revealing differential psychotic symptoms in schizophrenia and bipolar I disorder by manifold learning and network analyses.Translational psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms have long been considered a core component of schizophrenia. Modern conceptualizations of the structure of negative symptoms posit that there are at least two broad dimensions (motivation and pleasure and diminished expression) or perhaps five separable domains (avolition, anhedonia, asociality, blunted affect, alogia). The current review synthesizes a body of emerging research indicating that avolition may have a special place among these dimensions, as it is generally associated with poorer outcomes and may have distinct neurobiological mechanisms. Network analytic findings also indicate that avolition is highly central and interconnected with the other negative symptom domains in schizophrenia, and successfully remediating avolition results in global improvement in the entire constellation of negative symptoms. Avolition may therefore reflect the most critical treatment target within the negative symptom construct. Implications for targeted treatment development and clinical trial design are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.